Tislelizumab 联合化疗治疗 SMARCA4 缺陷型未分化肿瘤的成功治疗：一例报告。
Successful treatment with tislelizumab plus chemotherapy for SMARCA4-deficient undifferentiated tumor: a case report.
机构信息
Department of Oncology, Changde Hospital, Xiangya School of Medicine, Central South University (The First People's Hospital of Changde City), Changsa, China.
Department of Pathology, Changde Hospital, Xiangya School of Medicine, Central South University (The First People's Hospital of Changde City), Changsa, China.
出版信息
Front Immunol. 2024 May 31;15:1371379. doi: 10.3389/fimmu.2024.1371379. eCollection 2024.
SMARCA4-deficient undifferentiated tumor (SMARCA4-dUT) is a devastating subtype of thoracic tumor with SMARCA4 inactivation and is characterized by rapid progression, poor prognosis, and high risk of postoperative recurrence. However, effective treatments for SMARCA4-dUT are lacking. Herein, we describe a patient with SMARCA4-dUT who exhibited an impressive response to the anti-programmed cell death protein-1 (PD-1) antibody (tislelizumab) in combination with conventional chemotherapy (etoposide and cisplatin). To the best of our knowledge, this is the first case of SMARCA4-dUT treated with chemotherapy, comprising etoposide and cisplatin, combined with anti-PD-1 inhibitors. Immunotherapy combined with etoposide and cisplatin may be a promising strategy to treat SMARCA4-dUT.
SMARCA4 缺陷未分化肿瘤（SMARCA4-dUT）是一种具有 SMARCA4 失活的毁灭性胸部长瘤亚型，其特征为快速进展、预后不良和高术后复发风险。然而，针对 SMARCA4-dUT 的有效治疗方法仍缺乏。在此，我们描述了一例 SMARCA4-dUT 患者，其对程序性细胞死亡蛋白 1（PD-1）抗体（替雷利珠单抗）联合常规化疗（依托泊苷和顺铂）表现出显著反应。据我们所知，这是首例采用化疗（包含依托泊苷和顺铂）联合抗 PD-1 抑制剂治疗的 SMARCA4-dUT 病例。免疫疗法联合依托泊苷和顺铂可能是治疗 SMARCA4-dUT 的一种有前途的策略。
Zotero 插件